Alliance for Pharmacy Compounding

Shortage Drug Compounding and Semaglutide
For comprehensive APC statement, CLICK HERE.
For semaglutide primer for reporters, CLICK HERE.


What we're working on

We launched a 15-hour virtual CE programThe Ethical, Legal and Regulatory Foundations of Pharmacy Compounding–on August 1, 2023. Priced at $495, the program serves as entry-level training for compounding pharmacists and technicians.

We’re advocating for HR 167, legislation that would allow compounders temporarily to provide “urgent use” medications to hospitals and clinics when those drugs are in shortage. Read our recent op-ed in STAT.

We’re developing federal legislation that would:
Eliminate the MOU and replace it with reporting by pharmacies that ship more than 50 percent of their production out of state
• Establish an adverse event reporting framework for 503A pharmacies

We sent a memo to assist state boards of pharmacy in implementing and enforcing USP <797>.

We’re still working to save compounded hormones—therapies that benefit millions of Americans–in the wake of implicit threats to restrict them. Contribute to our ‘Compounding the Joy’ campaign.

We’re pushing back against FDA’s recent back-door reclassification of DTE as a biologic. 

We’re advising FDA to assure clear understanding of compliance standards and enforcement on GFI 256, regarding veterinary compounding. 

We’ve released a series of member-only briefing documents to help you educate prescribers about compounding on topics such as “The Truth About Pharmacy Compounding” and “Compounding Peptides: It’s Complicated.”

With amoxicillin in shortage, our advocacy resulted in FDA issuing guidance creating a path by which 503A pharmacies can more easily compound beta lactams.

We’ve launched a portal to help our members aggregate patient-reported outcomes to demonstrate that compounded medications are benefiting millions of patients–data that will be essential in making a case for cBHT if FDA moves to restrict it.

Via our Legal Action Fund, we filed two amicus briefs last year in court cases, one defending compounders’ right to compound methylcobalamin and another addressing ambiguity in FDA’s insanitary conditions guidance.

Upcoming Events

Now available on-demand: The FDA Compounding Quality Center of Excellence is announcing the availability of these self-guided, online courses:

September 19-20: APC’s Compounders on Capitol Hill 2023; Hilton National Mall; Washington, DC

September 28: An ARL Bio Pharma live webinar, Beyond The Survey: Top Findings and How to Implement Change in Your Pharmacy

October 5: An APC webinar, USP 797 Best Practices – It’s Not Just SOPs (Part 2): From Packaging to Handling, Stability, Documentation, and QA/QC 

October 24: An APC webinar, Internal Audit Processes – Facilitating Optimal Operations and Compliance of Your Compounding Pharmacy

October 26-28: PCCA’s International Seminar 2023 in Houston, TX

November 9: An APC webinar, Automation and USP 797 Don’t Mix. More details coming soon.

December 12: An APC webinar on quality assurance and medication/patient safety. More details coming soon.

April 4-6: Owner Summit, La Jolla, CA

June 20-21: EduCon Virtual: The Ethical Compounding Conference

Support Compounding